Molbio Diagnostics IPO: Price Band Set at Rs 768-807
Scientist operating a molecular diagnostic device in a laboratory
Key Highlights
Molbio Diagnostics sets its IPO price band at Rs 768-807 per share, aiming to raise Rs 904-940 crore. Funds to be used for infrastructure and equipment.
Molbio Diagnostics Ltd has set its (IPO) price band between Rs 768-807 per share. The point-of-care diagnostics company aims to raise between Rs 904 crore and Rs 940 crore through the share sale.
Key IPO Details
The IPO, backed by Temasek and Motilal Oswal Private Equity, includes both fresh shares and an Offer For Sale ().
- : Rs 768-807 per share
- Total Share Sale: Rs 904 crore – Rs 940 crore
- : Up to Rs 200 crore
- OFS: Up to 91.66 lakh equity shares
Window
Bidding for anchor investors begins on August 7. The main subscription period opens on August 10 and closes on August 12.
Planned Fund Utilization
The company plans to deploy fresh issue proceeds primarily for infrastructure development and equipment acquisition.
- Capital Expenditure: Rs 106 crore for R&D facility, Centre of Excellence, office space
- Equipment Purchase: Rs 72 crore for Goa Unit I, Goa Unit II, and Visakhapatnam unit
- Remaining Funds: General corporate purposes
Market Valuation & Investor Split
Molbio Diagnostics expects a post-issue market valuation of approximately Rs 9,300 crore at the upper price band.
- : 50% allocation
- Non-Institutional Investors: 15% allocation
- Investors: 35% allocation
Company Snapshot
Established in 2000, Molbio Diagnostics specializes in molecular testing for various diseases.
- Founded: 2000
- Diseases Tested: 30 (including tuberculosis, COVID, HIV, HPV, Hepatitis B and C)
- Platform: ‘Truenat’, patented in over 100 countries
- Installed Capacity (March 31, 2026): 5,400 devices and 3.9 crore Truenat test kits annually
- Manufacturing Facilities: Six across India
Fiscal 2026 Performance
For fiscal 2026, the company reported substantial revenue and profit figures.
- from Operations: Rs 1,445 crore
- Profit: Rs 164 crore